What ’s New in Therapy for Male Androgenetic Alopecia?
AbstractMale androgenetic alopecia is a common condition and represents a major concern for patients who experience this condition. While there are different treatments to stop hair loss and improve hair density, the 5-alpha reductase inhibitors have demonstrated to be effective in improving androgenetic alopecia in men and can maintain a positive response for many years. Oral finasteride 1 mg is a US FDA-approved option, but dutasteride 0.5 mg has been proven to induce better responses, especially in the frontal area. Both have been shown to be safe in clinical trials but there is widespread concern about sexual adverse...
Source: American Journal of Clinical Dermatology - September 28, 2022 Category: Dermatology Source Type: research
Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil in Japanese men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) tr... (Source: BMC Research Notes)
Source: BMC Research Notes - September 5, 2022 Category: Research Authors: Daisuke Gotoh, Kazumasa Torimoto, Yosuke Morizawa, Shunta Hori, Yasushi Nakai, Makito Miyake and Kiyohide Fujimoto Tags: Research note Source Type: research
32571 Intensive dutasteride mesotherapy protocol (IDMP) with oral minoxidil as an alternative to antiandrogens in AGA. A retrospective analysis of a hair restoration center
Background: Oral minoxidil (OM) is emerging as a safe and effective treatment for androgenetic alopecia (AGA). Intradermal microinjections of dutasteride may be a useful adjunctive therapy for AGA, however, information of its effectiveness is scarce. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - September 1, 2022 Category: Dermatology Authors: Estefania Boland-Rodr Íguez, César Daniel Villarreal-Villarreal, Abraham Benjamín Álfaro-Sánchez Source Type: research
Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia
J Dermatolog Treat. 2022 Aug 3:1-60. doi: 10.1080/09546634.2022.2109567. Online ahead of print.ABSTRACTBackground Androgenetic alopecia (AGA) is the most common cause of hair loss, often challenging to treat. While oral finasteride (1 mg/day) is an FDA-approved treatment for male AGA, oral minoxidil and oral dutasteride are not approved yet. However, clinicians have been increasingly using these two drugs off-label for hair loss. Recently, Japan and South Korea have approved oral dutasteride (0.5 mg/day) for male AGA.Efficacy and safety A probable efficacy ranking, in decreasing order, is- dutasteride 0.5 mg/day, finasteri...
Source: Journal of Dermatological Treatment - August 3, 2022 Category: Dermatology Authors: A K Gupta M Talukder G Williams Source Type: research
Peripheral Neuroprotective and Immunomodulatory Effects of 5 α-Reductase Inhibitors in Parkinson’s Disease Models
In conclusion, the present results indicate that dutasteride treatment prevents enteric neuronal damages in the MPTP mouse model, at least in part through anti-inflammatory and mitochondrial effects. This suggests that drug repurposing of dutasteride might be a promising avenue to treat enteric neuroinflammation in early PD. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - July 22, 2022 Category: Drugs & Pharmacology Source Type: research
Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice
CONCLUSION: Mesotherapy with dutasteride was effective in male and female hair loss in real clinical practice. Side effects related to the treatment were mild and self-limited. This therapy may be an effective option for select patients wishing to avoid oral treatment. J Drugs Dermatol. 2022;21(7):742-747. doi:10.36849/JDD.6610.PMID:35816059 | DOI:10.36849/JDD.6610 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 11, 2022 Category: Dermatology Authors: David Saceda-Corralo Farah Moustafa Óscar Moreno-Arrones Pedro Ja én-Olasolo Sergio Va ñó-Galván Francisco Camacho Source Type: research
